Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy (DCP) did not meet its primary or key secondary endpoints. The study's primary objective was to assess improvement in chorea, a type of involuntary movement, in individuals with DCP.
The KINECT-DCP trial is the largest double-blind, placebo-controlled clinical study ever conducted in DCP. It evaluated the efficacy, safety, and tolerability of 14 weeks of treatment with valbenazine compared to placebo in pediatric and adult participants experiencing dyskinesia due to cerebral palsy with choreiform movements.
Adverse events observed during the study were generally consistent with the established safety profile of valbenazine, reaffirming its known tolerability despite the lack of efficacy results in this indication.
Cerebral palsy (CP) is a nonprogressive neurodevelopmental disorder that affects movement and posture, starting in early childhood.
For More Such Health News, visit rttnews.com.
NBIX closed Monday's regular trading session at $147.53, up $2.53 or 1.74%. But in after-hours trading, the stock slipped to $146.16, down $1.37 or 0.93%.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.